These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14653607)

  • 1. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement.
    Mandelin J; Li TF; Liljeström M; Kroon ME; Hanemaaijer R; Santavirta S; Konttinen YT
    J Bone Joint Surg Br; 2003 Nov; 85(8):1196-201. PubMed ID: 14653607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
    Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
    Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing.
    Wilson SE; Mohan RR; Netto M; Perez V; Possin D; Huang J; Kwon R; Alekseev A; Rodriguez-Perez JP
    Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2201-11. PubMed ID: 15223796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation.
    Mandelin J; Liljeström M; Li TF; Ainola M; Hukkanen M; Salo J; Santavirta S; Konttinen YT
    J Biomed Mater Res B Appl Biomater; 2005 Jul; 74(1):582-8. PubMed ID: 15768436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin.
    Nagasawa T; Kobayashi H; Kiji M; Aramaki M; Mahanonda R; Kojima T; Murakami Y; Saito M; Morotome Y; Ishikawa I
    Clin Exp Immunol; 2002 Nov; 130(2):338-44. PubMed ID: 12390325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
    Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
    J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.
    Gehrke T; Sers C; Morawietz L; Fernahl G; Neidel J; Frommelt L; Krenn V
    Scand J Rheumatol; 2003; 32(5):287-94. PubMed ID: 14690142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
    Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
    Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
    Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin.
    Crotti TN; Smith MD; Findlay DM; Zreiqat H; Ahern MJ; Weedon H; Hatzinikolous G; Capone M; Holding C; Haynes DR
    Biomaterials; 2004 Feb; 25(4):565-73. PubMed ID: 14607494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars.
    Low E; Zoellner H; Kharbanda OP; Darendeliler MA
    Am J Orthod Dentofacial Orthop; 2005 Oct; 128(4):497-503. PubMed ID: 16214633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.
    Baumann B; Rader CP; Seufert J; Nöth U; Rolf O; Eulert J; Jakob F
    Acta Orthop Scand; 2004 Jun; 75(3):295-302. PubMed ID: 15260421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
    Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.